- \n
- New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth<\/i><\/b><\/li>\n<\/ul>\n
- \n
- Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue<\/i><\/b><\/li>\n<\/ul>\n
- \n
- Achieved GAAP and non-GAAP operating income of $13.3 million and $86.5 million for the second quarter 2026, respectively<\/i><\/b><\/li>\n<\/ul>\n
CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–
\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026.<\/p>\n\n\u201cAs I begin my tenure as CEO, I am excited by the strength of Sarepta’s foundation, the impact our therapies are having for patients, and the significant opportunities ahead,\u201d said Michael Severino, MD, chief executive officer, Sarepta Therapeutics. \u201cOur second quarter results, including $328.7 million in total net product revenue and both GAAP and non-GAAP operating profitability, reflect the strength and resilience of our business. With important data readouts expected in DM1 and FSHD, continued progress across our broader pipeline, and a talented team dedicated to transforming the lives of patients with rare diseases, we have significant opportunities ahead and remain committed to delivering sustainable long-term value. Our priorities are clear: execute our commercial strategy, advance our promising siRNA pipeline, and continue allocating capital with discipline. With a strong balance sheet, an innovative pipeline, and an experienced leadership team, I believe Sarepta is well positioned to deliver on its long-term potential.\u201d<\/p>\n
Corporate Highlights:<\/i><\/b><\/p>\n
- \n
- Leadership transition positions Sarepta for continued execution and next phase of growth: <\/b>Appointed Michael Severino, MD, as Chief Executive Officer and member of the Board of Directors, effective July 28, 2026. Dr. Severino brings more than 25 years of biopharmaceutical leadership experience, including senior executive roles at AbbVie, Amgen and Merck, and a proven track record of advancing innovation, building leading franchises and executing across the full development and commercialization continuum. Doug Ingram retired from Sarepta and will serve in an advisory capacity through the end of 2026 to support a seamless leadership transition.\n<\/li>\n
- Key 2H 2026 milestones update:<\/b> Readouts from our MAD cohorts of our ongoing phase 1\/2 studies in DM1 and FSHD remain on track for 2H 2026. For ELEVIDYS, full enrollment of ENDEAVOR Cohort 8 expected by year-end 2026 and 12-week data from the full cohort in Q1 2027.\n<\/li>\n
- Huntington\u2019s disease program advances:<\/b> Dosing underway in INSIGHTT, the first-in-human Phase 1 study of SRP-1005, Sarepta\u2019s investigational siRNA candidate for Huntington\u2019s disease.\n<\/li>\n
- Regulatory progress for PMO therapies: <\/b>FDA has accepted for review Sarepta\u2019s supplemental New Drug Applications (sNDAs) seeking conversion of AMONDYS 45 and VYONDYS 53 from accelerated to traditional approval. The applications are supported by data from the ESSENCE confirmatory study, substantial published real-world evidence, and the favorable, consistent safety profiles of both exon-skipping therapies.\n<\/li>\n
- Narrowed FY 2026 Guidance:<\/b> With six months remaining for the year and consistent with prior expectations toward the lower end of the $1.2-$1.4 billion range, Company narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion while also narrowing combined non-GAAP R&D and SG&A expense guidance from $800.0-$900.0 million to $800.0-$850.0 million.\n<\/li>\n
- Strong financial position supports advancement of our pipeline and funding of medium-term liabilities: <\/b>Delivered another quarter of operating profitability and ended with approximately $945.0 million of cash, cash equivalents, restricted cash and investments, an increase of approximately $197.0 million in the quarter. Company is well-positioned to advance DM1 and FSHD programs with commercial cash flows while maintaining disciplined capital allocation.\n<\/li>\n<\/ul>\n
Conference Call<\/i><\/b><\/p>\n
\nThe event will be webcast live under the investor relations section of Sarepta’s website at https:\/\/investorrelations.sarepta.com\/events-presentations<\/b><\/a> and following the event a replay will be archived there for one year. This event can be accessed using this link<\/b><\/a>.<\/b><\/p>\n
- Key 2H 2026 milestones update:<\/b> Readouts from our MAD cohorts of our ongoing phase 1\/2 studies in DM1 and FSHD remain on track for 2H 2026. For ELEVIDYS, full enrollment of ENDEAVOR Cohort 8 expected by year-end 2026 and 12-week data from the full cohort in Q1 2027.\n<\/li>\n
- Leadership transition positions Sarepta for continued execution and next phase of growth: <\/b>Appointed Michael Severino, MD, as Chief Executive Officer and member of the Board of Directors, effective July 28, 2026. Dr. Severino brings more than 25 years of biopharmaceutical leadership experience, including senior executive roles at AbbVie, Amgen and Merck, and a proven track record of advancing innovation, building leading franchises and executing across the full development and commercialization continuum. Doug Ingram retired from Sarepta and will serve in an advisory capacity through the end of 2026 to support a seamless leadership transition.\n<\/li>\n
- Achieved GAAP and non-GAAP operating income of $13.3 million and $86.5 million for the second quarter 2026, respectively<\/i><\/b><\/li>\n<\/ul>\n
- Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue<\/i><\/b><\/li>\n<\/ul>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260805692741\/en\/1815332\/3\/Sarepta_Corporate-_Stacked_Logo_%28Full_Color%29.jpg\"){kind=logo}
<\/td>\n<\/tr>\n